Kineta Operating Income 2014-2024 | KANT
Kineta operating income from 2014 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Kineta Annual Operating Income
(Millions of US $) |
| 2023 |
$-16 |
| 2022 |
$-42 |
| 2021 |
$-11 |
| 2020 |
$-56 |
| 2019 |
$-30 |
| 2018 |
$-63 |
| 2017 |
$-60 |
| 2016 |
$-37 |
| 2015 |
$-25 |
| 2014 |
$-16 |
| 2013 |
$-16 |
Kineta Quarterly Operating Income
(Millions of US $) |
| 2024-06-30 |
$-3 |
| 2024-03-31 |
$-6 |
| 2023-12-31 |
$-4 |
| 2023-09-30 |
$-4 |
| 2023-06-30 |
$-1 |
| 2023-03-31 |
$-6 |
| 2022-12-31 |
$-27 |
| 2022-09-30 |
$-4 |
| 2022-06-30 |
$-5 |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$18 |
| 2021-09-30 |
$-10 |
| 2021-06-30 |
$-10 |
| 2021-03-31 |
$-9 |
| 2020-12-31 |
$-36 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$24 |
| 2019-09-30 |
$-13 |
| 2019-06-30 |
$-21 |
| 2019-03-31 |
$-15 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-19 |
| 2018-06-30 |
$-16 |
| 2018-03-31 |
$-11 |
| 2017-12-31 |
$-14 |
| 2017-09-30 |
$-14 |
| 2017-06-30 |
$-17 |
| 2017-03-31 |
$-15 |
| 2016-12-31 |
$-10 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-6 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-5 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
